Republic of Korea-based biopharma company Celltrion is looking to accelerate its momentum in Europe; analysts belive that the company could receive the European Medicines Agency’s (EMA) approval to market its biosimilar of Roche’s blockbuster cancer treatment, Herceptin (trastuzumab), by March 2018.
Republic of Korea-based biopharma company Celltrion is looking to accelerate its momentum in Europe; according to The Investor, analysts believe that the company could receive the European Medicines Agency’s (EMA) approval to market its biosimilar of Roche’s blockbuster cancer treatment, Herceptin (trastuzumab), by March 2018.
Celltrion’s proposed trastuzumab biosimilar is the company’s third biosimilar product pursuing access to the European market, following the launch of Remsima, an infliximab biosimilar of Johnson & Johnson’s reference Remicade, and a rituximab biosimilar, Truxima, referenced on Rituxan.
“Herzuma will be well positioned for Celltrion to have confidence in sales based on 4 years of market experience (in Europe) and a strong partner network,” Park Si-hyeong, an analyst at IBK Securities, told The Investor.
Most recently, the FDA approved Mylan and Biocon's trastuzumab biosimilar, Ogivri. Other Herceptin products in development for the US and EU markets include:
In addition to its trastuzumab biosimilar, Celltrion is developing several other notable products:
The Investor reports that an official at Celltrion has indicated that Herzuma will be able to hit the European market 3 months after approval. Celltrion has not decided yet on its marketing partner for the drug, but it is likely to continue to work with existing partners such as Mundipharma, Biogaran, and Kern Pharma.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.